Post-Market Surveillance of Tobacco Products

Smoking, Tobacco Clinical Trial

Official title:

Post-Market Surveillance of Tobacco Products: A Multicenter Clinical Trial of Natural Adopters of Cigarettes, Moist Snuff, Camel SNUS, and Dual Use

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04255459
• Other study ID #: CSD0904
• Status: Completed
• Phase: N/A
• Start date: February 13, 2010
• Est. completion date: August 14, 2010

Study information

• Verified date: January 2020
• Source: RAI Services Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, post market surveillance study designed to evaluate biomarkers of tobacco exposure and effect, health status measurements, and tobacco product usage patterns in subjects who are natural adopters of cigarettes and/or smokeless tobacco. Non tobacco users will serve as a non use comparison group. This study is unblinded by necessity due to the very different visual appearance of the subject's Usual Brand (UB) of tobacco product(s).

Description:

A total of approximately 320 subjects will be enrolled in parallel in one of the following 6 cohorts based on tobacco usage:

• Exclusive moist snuff users (n=50)

• Exclusive Camel SNUS users (n=50)

• Dual users of Camel SNUS and cigarettes (n=50)

• Dual users of moist snuff and cigarettes (n=50)

• Exclusive cigarette smokers (n=40 males and 20 females)

• Non tobacco users (n=40 males and 20 females)

The study duration will be 5.5 weeks or less, depending upon the study procedures required for the subject's specific cohort. The study duration includes screening up to 35 days prior to clinic check in (Day 1) and a 2 day confinement period of approximately 24 hours (Day 1 and Day 2). Subjects will be discharged in the morning on Day 2.

At the Initial Screening Visit, clinical study staff will perform screening assessments. Tobacco users will be instructed to provide a sufficient supply of their UB product(s) for use during pre-clinic procedures (i.e., pre-clinic used tobacco product collections) and for use during clinic confinement.

Prior to checking in for clinic confinement, subjects will return to the clinic for a Pre-Enrollment Outpatient Visit to assess enrollment eligibility related to the safe completion of triplicate spirometry and to pick up used tobacco product collection kits and/or urine collection containers for pre-clinic collection procedures. Within 14 days prior to clinic admission, subjects will be instructed, depending on their tobacco cohort, to continue smoking and/or using Camel SNUS or moist snuff at their normal rates and to collect their used cigarette butts (1 day collection) and/or used snus pouches (7 day collection), and retain the labeled snuff containers (1 day usage). Subjects will turn in their used tobacco product collections upon clinic check in.

Subjects will report to the clinical research unit in the morning on Day 1 for baseline testing, confirmation of continued study eligibility, check in of their UB tobacco product(s), and return of their urine collection containers and used tobacco product collections. Subjects will be allowed to use their UB tobacco product(s) ad libitum; tobacco products will be stored by clinic staff and will be dispensed subsequent to subject request, as allowed during scheduled study procedures (i.e., questionnaires, spirometry, carboxyhemoglobin, 6MWT [six-minute walk test]). Each UB product usage will be recorded. At approximately 2200, fasting (from all food and drink except water) and tobacco abstention will begin. Subjects must agree to remain abstinent for approximately 8-10 hours and until all Day 2 fasting procedures (i.e., samples for biomarkers of tobacco effect and exposure) have been completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 320
• Est. completion date: August 14, 2010
• Est. primary completion date: August 14, 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Able to comprehend and willing to sign an informed consent form.

2. Male or female subjects at least 19 years of age.

3. Able to safely perform all study procedures, as determined by the site Investigator.

4. Willing to perform all study procedures and to consume only the meals/snacks provided while confined to the clinic.

5. Agree to not use drugs of abuse over the course of the study, and test negative for drugs of abuse.

6. Test negative for breath alcohol (by breathalyzer).

7. For tobacco users: do NOT intend to quit smoking nor intend to quit using oral smokeless tobacco products (STP) leading up to study participation (defined as planning a quit attempt within a month of the Initial Screening Visit).

8. For tobacco users: willing to abstain from tobacco use for up to 10 hours during overnight confinement in the clinic.

9. Able to read, understand, and complete questionnaires in English.

10. Meet cohort specific requirements as follows:

• Moist Snuff Users: Must be exclusive moist snuff users of any brand, any style, and any flavor who self-report using on average = 1 can per week for at least 6 months prior to study entry, have an expired carbon monoxide (ECO) level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.

• Camel SNUS Users: Must be exclusive Camel SNUS users of any variety who self report using on average = 1 tin per week for at least 6 months prior to study entry, have an ECO level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.

• Dual Camel SNUS/Cigarette Users: Must be dual users of Camel SNUS and allowed commercial filtered tobacco burning cigarettes, using on average = 1 tin of Camel SNUS per week and smoking = 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.

• Dual Moist Snuff/Cigarette Users: Must be dual users of moist snuff and allowed commercial filtered tobacco burning cigarettes, using on average = 1 can of snuff per week and smoking = 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.

• Cigarette Smokers: Must be exclusive cigarette smokers (of allowed commercial filtered tobacco burning cigarettes) who self-report smoking on average = 10 cigarettes daily for at least 6 months prior to study entry, have an ECO level of 10 to 100 ppm, and have a positive urine cotinine screen.

• Non Tobacco Users: Must be non tobacco users for at least 12 months prior to study entry with an ECO level of 0 to 5 ppm, and have a negative urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.

Exclusion Criteria:

1. Use of any type of non-tobacco nicotine-containing product/device (e.g., electronic cigarette) or any nicotine replacement therapy (e.g., nicotine patch, nicotine gum, nicotine spray, nicotine inhaler or nicotine lozenge) within 6 months prior to study entry or during the study.

2. Unable to safely perform the study procedures, as determined by the site Investigator. In general, subjects with any of the conditions listed below will be excluded unless individually approved by the Medical Monitor.

1. Uncontrolled hypertension (blood pressure > 170/110 mmHg at the Initial Screening Visit).

2. Unstable coronary artery disease (Class III-IV angina).

3. Decompensated (Class III-IV) congestive heart failure.

4. Morbid obesity (body mass index [BMI] = 40 kg/m2).

5. Uncontrolled diabetes (HgbA1c > 9.0).

6. Pulmonary disease requiring oxygen therapy or preventing 6 minutes of steady ambulation or preventing completion of triplicate spirometry.

7. Reduced mobility that impairs satisfactory completion of the 6MWT (six minute walk test), such as:

i. Clinically significant arthritis of the knee or hip.

ii. Claudication with walking 6 minutes or less.

iii. Clinically significant ambulation impairment as sequelae of cerebrovascular accident (CVA), sciatica, peripheral nervous disease, or myopathy.

iv. Imbalance or other gait disorder requiring assistance of a cane or walker to ambulate.

3. Have a resting heart rate (after being seated for at least 5 minutes) of > 120 beats per minute (bpm).

4. Had a myocardial infarction within the month prior to the Initial Screening Visit through enrollment into the study.

5. Have self reported or clinical indications of psychiatric disorders deemed clinically significant by the site Investigator.

6. Unwilling to perform the study procedures.

7. For females: intend to get pregnant during study period, or are currently pregnant or breast feeding.

8. For cigarette- and dual-users:

1. use of any charcoal-filtered cigarette (i.e., brands such as Lark, Kent, etc., with the word "charcoal" on the package),

2. use of any crush-capsule cigarette (such as Camel Crush or Pall Mall Crush), or

3. use of any non tobacco burning cigarette, including tobacco heating cigarettes (such as Eclipse, Accord, etc.) or electronic cigarettes (e-cigarettes such as Smoking Anywhere, Gamucci, NJOY, etc.).

9. For tobacco users: express an interest in quitting smoking or using oral smokeless tobacco (defined as planning a quit attempt within a month of the Initial Screening Visit).

10. Have participated in a clinical study and/or received an investigational product within 30 days of the Initial Screening Visit.

11. Meet cohort specific exclusions as follows:

• Moist Snuff Users: For 6 months prior to the study through Day 1, the use of any other tobacco- or nicotine-containing product or device other than moist snuff (of any brand, style, and flavor), including tobacco-burning cigarettes, tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, snus, etc.; a negative urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).

• Camel SNUS Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than Camel SNUS (of any variety), including tobacco-burning cigarettes, tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, other snus brands, etc.; a negative urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).

• Dual Camel SNUS/Cigarette Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than Camel SNUS (of any variety) and tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, other snus brands, etc.; a negative urine cotinine screen; or an ECO less than 5 or greater than 100 ppm.

• Dual Moist Snuff/Cigarette Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than moist snuff (of any brand, style, and flavor) and tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, snus, etc.; a negative urine cotinine screen; or an ECO less than 5 or greater than 100 ppm.

• Cigarette Smokers: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, snus, etc.; a negative urine cotinine screen; or an ECO less than 10 or greater than 100 ppm.

• Non Tobacco Users: In their lifetime, the use of more than 20 packs of cigarettes; the use of more than 10 cans, tins, or packs of any smokeless tobacco (chewing tobacco, dry snuff, moist snuff, snus); the use of more than 20 cigars; the use of more than 20 pipes of tobacco; the use of any nicotine replacement therapy, the use of any e cigarette, or use of any combination thereof; a positive urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).

Related Conditions & MeSH terms

• Smoking Behaviors
• Smoking, Tobacco

Intervention

Other:
• Moist Snuff
Moist Snuff product
• Camel Snus
Camel Snus product
• Cigarettes
Cigarette product
• No tobacco usage
No tobacco usage

Locations

Country	Name	City	State
United States	Community Clinical Research	Austin	Texas
United States	MetaClin Research, Inc.	Austin	Texas
United States	Avail Clinical Research	DeLand	Florida
United States	Central Kentucky Research Associates (CKRA)	Lexington	Kentucky
United States	Comprehensive Clinical Development, Inc.	Miramar	Florida
United States	Clinical Research Atlanta	Stockbridge	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
RAI Services Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urine creatinine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Urine nicotine and 9 metabolites	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Tobacco specific nitrosamines in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Acrolein metabolite and acrylamide metabolites in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Crotonaldehyde metabolite in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Benzene metabolite in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	1,3 Butadiene metabolites in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Aromatic amines in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Polycyclic aromatic hydrocarbons metabolites in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Thiocyanate in urine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Urinary mutagen uptake in strains TA98 and YG1024	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Isoprostanes and metabolites; prostaglandin PGF2alpha in urine	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Blood nicotine and cotinine	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Thiocyanate in blood	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Carboxyhemoglobin in blood	To establish baseline values for tobacco exposure biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	4-Aminobiphenyl hemoglobin adducts in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Amino Acids in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Glycated hemoglobin in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Total cholesterol in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Triglycerides in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Low density lipoprotein cholesterol in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	High density lipoprotein cholesterol in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Very low density lipoprotein cholesterol in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Apolipoprotein A1 in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Apolipoprotein A2 in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Apolipoprotein B100 in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Lipoprotein(a) in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Oxidized low density lipoprotein in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Folate in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Fibrinogen in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Tissue inhibitor of metalloproteinase 1 in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	hsC-reactive protein in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	alpha-1-antitrypsin in blood	To establish baseline values for tobacco effect biomarker levels of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Tar (mg/day) and nicotine (mg/day) from subject's in-clinic cigarette use OR nicotine (mg/day) from subject's in-clinic snus use	To establish baseline values for mouth-level exposure of natural adopters for the product classes of cigarettes and snus.	After 1 day of product usage
Primary	Functional capacity of subjects completing a 6 Minute Walk Test (6MWT) as assessed by the Dyspnea Modified Borg Scale, pre- and post-6MWT.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Functional capacity of subjects completing a 6 Minute Walk Test (6MWT) as assessed by the Overall Fatigue Modified Borg Scale, pre- and post-6MWT.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Functional capacity of subjects completing a 6 Minute Walk Test (6MWT) as assessed by heart rate (beats/minute), pre- and post-6MWT.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Functional capacity of subjects completing a 6 Minute Walk Test (6MWT) as assessed by oxygen saturation (% SpO2), pre- and post-6MWT.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Functional capacity of subjects completing a 6 Minute Walk Test (6MWT) as assessed by spirometry (FEV1 % predicted), pre- and post-6MWT.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Functional capacity of subjects completing a 6 Minute Walk Test (6MWT) as assessed by spirometry (FEV1 /FVC ratio), pre- and post-6MWT.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Current self-reported health status as measured by the Fagerström Test for Nicotine Dependence.	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Current self-reported health status as measured by the Smoking Cessation Quality of Life Questionnaire (SCQoL, inclusive of the Short Form Health Survey [SF-36v2]).	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage
Primary	Current self-reported health status as measured by the American Thoracic Society Division of Lung Disease Questionnaire (ATS-DLD-78-A).	To establish baseline values for health status of natural adopters of each product class and of non-tobacco users.	After 1 day of product usage